APA (7th ed.) Citation

Hughes, D. A., Nicholls, K., Sunder‐Plassmann, G., Jovanovic, A., Feldt‐Rasmussen, U., Schiffmann, R., . . . Bichet, D. G. (2019). Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study. American Journal of Medical Genetics. Part A, 179(6), 1069. https://doi.org/10.1002/ajmg.a.61105

Chicago Style (17th ed.) Citation

Hughes, Derralynn A., et al. "Safety of Switching to Migalastat from Enzyme Replacement Therapy in Fabry Disease: Experience from the Phase 3 ATTRACT Study." American Journal of Medical Genetics. Part A 179, no. 6 (2019): 1069. https://doi.org/10.1002/ajmg.a.61105.

MLA (9th ed.) Citation

Hughes, Derralynn A., et al. "Safety of Switching to Migalastat from Enzyme Replacement Therapy in Fabry Disease: Experience from the Phase 3 ATTRACT Study." American Journal of Medical Genetics. Part A, vol. 179, no. 6, 2019, p. 1069, https://doi.org/10.1002/ajmg.a.61105.